Symmetric drug–related intertriginous and flexural exanthema–like eruption related to coronavirus disease 2019 vaccine

Abstract

received the second dose of the coronavirus disease 2019 (COVID-19) vaccine (ChAdOx1 nCoV-19 [AstraZeneca]). He denied taking any medication or supplements within 2 months before and after the second vaccination. He also denied history of any other contact or exposure. After the first injection of the COVID-19 vaccine, no adverse events occurred. Physical examination showed well-demarcated erythematous macular patches distributed symmetrically over the axillary and inguinal areas, with skin desquamation and swelling in the scrotal area and on the glans penis (Figure 1A-C). Systemic signs were absent. The blood test results were normal. Findings of direct F I G U R E 1 (A) A 53-year-old man in whom erythematous maculopatches that were distributed symmetrically over the axillary, inguinal, and perigenital areas developed 10 days after COVID-19 vaccination (ChAdOx1 nCoV-19). (B, C) Involvement of both axillary areas and the characteristic V-shaped erythema of the inguinal/perigenital area How to cite this article: Hong JK, Shin SH, Yoo KH, Li K, Seo SJ. Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine.

Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings

“…1 Till now, only a few cases of SDRIFE-like rashes have been reported in the setting of coronavirus disease 2019 (COVID-19) or vaccination. [2][3][4][5] We aim to discuss its relation to COVID-19 and vaccination with this series of three patients.…”